Australia records fewer pregabalin (a gabapentinoid) prescriptions and a drop in overdoses after a period of heightened public attention, according to a retrospective analysis. Both outlets describe the change as occurring from around 2018 onward, with the declines attributed to a combination of factors rather than a single intervention.
The reports link the shift to high-profile media coverage about pregabalin harms alongside tighter prescribing restrictions, supply-related changes, and updated warnings. One account also frames the outcome around the timing of media attention and regulatory safeguards, while the other emphasizes public awareness and policy measures as contributors to reduced misuse. In both summaries, the study’s findings are presented as evidence that prescribing restrictions and risk communication align with improvements in use and overdose trends in Australia.
While the outlets focus on slightly different emphases—one on the impact on overdose and prescriptions, the other on misuse and awareness—the core message is consistent: after 2018, Australia’s pregabalin misuse indicators decline in parallel with media coverage and stricter controls.
